Chan Lee - BeiGene General VP

BGNE Stock  USD 206.16  14.05  7.31%   

VP

Chan Lee is General VP of BeiGene
Age 56
Address 94 Solaris Avenue, Camana Bay, Cayman Islands, KY1-1108
Phone345-949-4123
Webhttps://www.beigene.com

Chan Lee Latest Insider Activity

Tracking and analyzing the buying and selling activities of Chan Lee against BeiGene stock is an integral part of due diligence when investing in BeiGene. Chan Lee insider activity provides valuable insight into whether BeiGene is net buyers or sellers over its current business cycle. Note, BeiGene insiders must abide by specific rules, including filing SEC forms every time they buy or sell BeiGene'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

BeiGene Management Efficiency

The company has return on total asset (ROA) of (0.0958) % which means that it has lost $0.0958 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2322) %, meaning that it created substantial loss on money invested by shareholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.32. At present, BeiGene's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 37.5 M, whereas Other Assets are forecasted to decline to 1.90.
BeiGene currently holds 930.18 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. BeiGene has a current ratio of 4.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BeiGene's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 13 records

VP Age

Sandra CalvinTravere Therapeutics
58
Peter RasmussenAscendis Pharma AS
55
James CPAApellis Pharmaceuticals
57
Sheila JDIncyte
58
Elizabeth JDTravere Therapeutics
53
Brian MuellerBiomarin Pharmaceutical
50
Elaine QianLegend Biotech Corp
N/A
Brinda MDBiomarin Pharmaceutical
44
George DavisBiomarin Pharmaceutical
53
Mikhail JDVaxcyte
42
Elizabeth ReedTravere Therapeutics
53
George JDBiomarin Pharmaceutical
53
Nadia MBAArrowhead Pharmaceuticals
N/A
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Beigene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8600 people. BeiGene (BGNE) is traded on NASDAQ Exchange in USA. It is located in 94 Solaris Avenue, Camana Bay, Cayman Islands, KY1-1108 and employs 10,600 people. BeiGene is listed under Biotechnology category by Fama And French industry classification.

Management Performance

BeiGene Leadership Team

Elected by the shareholders, the BeiGene's board of directors comprises two types of representatives: BeiGene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeiGene. The board's role is to monitor BeiGene's management team and ensure that shareholders' interests are well served. BeiGene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeiGene's outside directors are responsible for providing unbiased perspectives on the board's policies.
Xiaodong Wang, CoChairman CoFounder
John Oyler, Chairman of the Board, CEO, Founder
Mi Zhou, Director Relations
Liza Heapes, Head Relations
Chan Lee, General VP
Wang Lai, Global RD
Kevin Mannix, VP Relations
Titus Ball, VP Officer
Julia Wang, Executive Officer
Aaron Rosenberg, CFO Officer
Jason Radford, Senior Development
Yang Ji, Chief Officer
Daniel Maller, VP Accounting
Jaspreet MD, Senior Strategy
Diana Francis, VP Compliance
Melika Davis, Clinical Head
Yan Qi, Senior China
Xiaobin Wu, President COO

BeiGene Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BeiGene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeiGene. If investors know BeiGene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeiGene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.18)
Revenue Per Share
225.239
Quarterly Revenue Growth
0.395
Return On Assets
(0.1)
Return On Equity
(0.23)
The market value of BeiGene is measured differently than its book value, which is the value of BeiGene that is recorded on the company's balance sheet. Investors also form their own opinion of BeiGene's value that differs from its market value or its book value, called intrinsic value, which is BeiGene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeiGene's market value can be influenced by many factors that don't directly affect BeiGene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.